Meyer Handelman CO Gilead Sciences, Inc. Transaction History

Meyer Handelman CO

$2.92 Billion
Q3 2024

A detailed history of Meyer Handelman CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Meyer Handelman CO holds 370,884 shares of GILD stock, worth $32.9 Million. This represents 1.06% of its overall portfolio holdings.

Number of Shares

370,884

Previous 383,369 3.26%

Holding current value

$32.9 Million

Previous $26.3 Million 18.19%

% of portfolio

1.06%

Previous 0.93%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$66.59 - $83.99 $831,376 - $1.05 Million	-12,485 Reduced 3.26%	370,884 $31.1 Million
Q2 2024 Jul 16, 2024	SELL	$63.15 - $72.88 $552,120 - $637,189	-8,743 Reduced 2.23%	383,369 $26.3 Million
Q1 2024 Apr 11, 2024	BUY	$71.58 - $87.29 $43,878 - $53,508	613 Added 0.16%	392,112 $28.7 Million
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $62,645 - $71,041	-855 Reduced 0.22%	391,499 $31.7 Million
Q3 2023 Nov 06, 2023	BUY	$73.94 - $80.67 $658,066 - $717,963	8,900 Added 2.32%	392,354 $29.4 Million
Q2 2023 Jul 21, 2023	SELL	$76.01 - $86.7 $795,824 - $907,749	-10,470 Reduced 2.66%	383,454 $29.6 Million
Q1 2023 Apr 11, 2023	SELL	$77.31 - $88.08 $2.32 Million - $2.64 Million	-29,950 Reduced 7.07%	393,924 $32.7 Million
Q4 2022 Jan 25, 2023	SELL	$62.32 - $89.47 $726,028 - $1.04 Million	-11,650 Reduced 2.67%	423,874 $36.4 Million
Q3 2022 Oct 04, 2022	SELL	$59.54 - $68.01 $38,701 - $44,206	-650 Reduced 0.15%	435,524 $26.9 Million
Q2 2022 Jul 15, 2022	SELL	$57.72 - $65.01 $14,430 - $16,252	-250 Reduced 0.06%	436,174 $27 Million
Q1 2022 Apr 06, 2022	SELL	$57.92 - $72.58 $46,336 - $58,064	-800 Reduced 0.18%	436,424 $25.9 Million
Q4 2021 Jan 25, 2022	BUY	$64.88 - $73.64 $895,343 - $1.02 Million	13,800 Added 3.26%	437,224 $31.7 Million
Q3 2021 Nov 01, 2021	BUY	$67.69 - $73.03 $263,991 - $284,817	3,900 Added 0.93%	423,424 $29.6 Million
Q2 2021 Aug 18, 2021	BUY	$63.47 - $69.35 $698,170 - $762,849	11,000 Added 2.69%	419,524 $28.9 Million
Q1 2021 May 03, 2021	BUY	$60.0 - $68.46 $1.96 Million - $2.24 Million	32,675 Added 8.69%	408,524 $26.4 Million
Q4 2020 Feb 03, 2021	BUY	$56.65 - $64.55 $997,040 - $1.14 Million	17,600 Added 4.91%	375,849 $21.9 Million
Q3 2020 Oct 28, 2020	BUY	$62.1 - $78.08 $121,095 - $152,256	1,950 Added 0.55%	358,249 $22.6 Million
Q2 2020 Jul 16, 2020	BUY	$72.34 - $84.0 $94,042 - $109,200	1,300 Added 0.37%	356,299 $27.4 Million
Q1 2020 Apr 22, 2020	BUY	$62.63 - $80.22 $901,809 - $1.16 Million	14,399 Added 4.23%	354,999 $26.5 Million
Q4 2019 Jan 23, 2020	BUY	$61.62 - $67.78 $117,694 - $129,459	1,910 Added 0.56%	340,600 $22.1 Million
Q3 2019 Oct 07, 2019	BUY	$62.51 - $69.0 $736,992 - $813,510	11,790 Added 3.61%	338,690 $21.5 Million
Q2 2019 Jul 23, 2019	BUY	$61.87 - $69.38 $454,744 - $509,942	7,350 Added 2.3%	326,900 $22.1 Million
Q1 2019 Apr 30, 2019	BUY	$62.53 - $70.05 $318,903 - $357,255	5,100 Added 1.62%	319,550 $20.6 Million
Q4 2018 Feb 05, 2019	BUY	$60.54 - $79.0 $1.63 Million - $2.13 Million	27,000 Added 9.39%	314,450 $19.7 Million
Q3 2018 Nov 06, 2018	BUY	$71.28 - $78.92 $49,896 - $55,244	700 Added 0.24%	287,450 $22.2 Million
Q2 2018 Jul 30, 2018	SELL	$64.88 - $75.68 $209,043 - $243,840	-3,222 Reduced 1.11%	286,750 $20.3 Million
Q1 2018 Apr 23, 2018	BUY	$72.84 - $88.8 $116,544 - $142,080	1,600 Added 0.55%	289,972 $21.9 Million
Q4 2017 Feb 07, 2018	SELL	$71.15 - $83.52 $8.57 Million - $10.1 Million	-120,412 Reduced 29.46%	288,372 $20.7 Million
Q3 2017 Oct 25, 2017	BUY	$72.11 - $85.47 $29.5 Million - $34.9 Million	408,784	408,784 $33.1 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meyer Handelman CO, based on Form 13F filings with the SEC.

News

Stay updated on Meyer Handelman CO with notifications on news.

Account

Meyer Handelman CO Gilead Sciences, Inc. Transaction History